Abstract
Radiation-induced genomic instability encompasses a range of measurable end points such as chromosome destabilization, sister chromatid exchanges, gene mutation and amplification, late cell death and aneuploidy, all of which may be causative factors in the development of clinical disease, including carcinoma. Clinical implications of genomic instability can be broadly grouped into two main areas: as a marker for increased cancer risk/early detection, and as a consequence of radiation therapy (IR) that may be causative of, or a strong marker for, the induction of a therapy-induced second malignancy. Research in human populations has been limited, but broadly encompasses three populations: those exposed to α-particle irradiation, those with a cancer diagnosis who were examined for lymphocyte sensitivity to IR as a biomarker for risk of cancer induction, and those who successfully completed radiation therapy for an index cancer and who were examined for the induction of a second malignancy. This review examines each of those populations in turn and offers some potential future research directions to better elucidate the role of radiation-induced genomic instability in clinical disease.
Similar content being viewed by others
References
Al-Maghrabi J, Vorobyova L, Chapman W, Jewett M, Zielenska M and Squire JA . (2001). Mod. Pathol., 14, 1252–1262.
Behrens C, Travis LB, Wistuba II, Davis S, Maitra A, Clarke EA, Lynch CF, Glimelius B, Wiklund T, Tarone R and Gazdar AF . (2000). Cancer Epidemiol. Biomarkers Prev., 9, 1027–1035.
Buchholz TA and Wu X . (2001). Int. J. Radiat. Oncol. Biol. Phys., 49, 533–537.
Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F and Cox JD . (2003). Int. J. Radiat. Oncol. Biol. Phys., 55, 36–43.
Colleu-Durel S, Guitton N, Nourgalieva K, Leveque J, Danic B and Chenal C . (2001). Oncol. Rep., 8, 1001–1005.
Dann EJ and Rowe JM . (2001). Best Pract. Res. Clin. Haematol., 14, 119–137.
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, Van't Veer MB, Stovall M, Gospodarowicz M and Travis LB . (2002). J. Clin. Oncol., 20, 3484–3494.
Dorr W and Herrmann T . (2002). J. Radiol. Prot., 22, A117–A121.
Fearon ER and Vogelstein B . (1990). Cell, 61, 759–767.
Finette BA, Homans AC and Albertini RJ . (2000). Science, 288, 514–517.
Hande MP, Azizova TV, Geard CR, Burak LE, Mitchell CR, Khokhryakov VF, Vasilenko EK and Brenner DJ . (2003). Am. J. Hum. Genet., 72, 1162–1170.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD . (1999). J. Clin. Oncol., 17, 3835–3849.
Hartmann Siantar CL, Walling RS, Daly TP, Faddegon B, Albright N, Bergstrom P, Bielajew AF, Chuang C, Garrett D, House RK, Knapp D, Wieczorek DJ and Verhey LJ . (2001). Med. Phys., 28, 1322–1337.
Hsu TC, Spitz MR and Schantz SP . (1991). Cancer Epidemiol. Biomarkers Prev., 1, 83–89.
Kadhim MA, Lorimore SA, Hepburn MD, Goodhead DT, Buckle VJ and Wright EG . (1994). Lancet, 344, 987–988.
Kadhim MA, Lorimore SA, Towensend KM, Goodhead DT, Buckle VJ and Wright EG . (1995). Int. J. Radiat. Biol., 67, 287–293.
Kadhim MA, Macdonald DA, Goodhead DT, Lorimore SA, Marsden SJ and Wright EG . (1992). Nature, 355, 738–740.
Kryscio A, Ulrich Muller WU, Wojcik A, Kotschy N, Grobelny S and Streffer C . (2001). Int. J. Radiat. Biol., 77, 1087–1093.
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR and Willman CL . (1999). Blood, 94, 1086–1099.
Limoli CL, Kaplan MI, Giedzinski E and Morgan WF . (2001). Free Radic. Biol. Med., 31, 10–19.
Liu D, Momoi H, Li L, Ishikawa Y and Fukumoto M . (2002). Int. J. Cancer, 102, 366–371.
Matheson JB, Burmeister BH, Smithers BM, Gotley D, Harvey JA and Doyle L . (2002). Radiother. Oncol., 65, 159–163.
Pickles T and Phillips N . (2002). Radiother. Oncol., 65, 145–151.
Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG and Scott D . (1999). Am. J. Hum. Genet., 65, 784–794.
Schmidberger H, Virsik-Koepp P, Rave-Frank M, Reinosch KR, Pradler O, Munzel U and Hess CF . (2001). Int. J. Radiat. Oncol. Biol. Phys., 50, 857–864.
Scott D, Barber JB, Spreadborough AR, Burrill W and Roberts SA . (1999). Int. J. Radiat. Biol., 75, 1–10.
Tawn EJ, Whitehouse CA and Martin FA . (2000). Mutat. Res., 465, 45–51.
Watson GE, Lorimore SA and Wright EG . (1996). Int. J. Radiat. Biol., 69, 175–182.
Whitehouse CA and Tawn EJ . (2001). Radiat. Res., 156 (5 Part 1), 467–475, 7587.
Zablotska LB and Neugut AI . (2003). Cancer, 97, 1404–1411.
Zhang H, Buchholz TA, Hancock D, Spitz MR and Wu X . (2000). Int. J. Oncol., 17, 399–404.
Acknowledgements
This work was in part supported by the Office of Science (BER), U.S. Department of Energy grant #DE-FG03-01ER63237 and the Office of the President, University of California, CLC Grant number 69895.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldberg, Z. Clinical implications of radiation-induced genomic instability. Oncogene 22, 7011–7017 (2003). https://doi.org/10.1038/sj.onc.1206990
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206990
- Springer Nature Limited
Keywords
This article is cited by
-
Secondary malignancy after radiotherapy: not always a secondary concern
Nature Reviews Urology (2021)
-
Risk of Second Primary Malignancies in Lung Cancer Survivors – The Influence of Different Treatments
Targeted Oncology (2017)
-
Irradiation induces DNA damage and modulates epigenetic effectors in distant bystander tissue in vivo
Oncogene (2006)